Research: Clinical Trials Unit

Studies open for recruitment - Liver Studies

1. Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (REACH).

   For more information, click here.

2. Efficacy and Safety Study of DEB025/Alisporivir Combined to Standard Therapy (Peg-IFN and Ribavirin) in Chronic Hepatitis C Genotype 1 naïve Patients.

   For more information, click here.

3. A Phase 2 Randomized, Open-Label, Exploratory Trial of GS-5885, GS-9451 with Peginterferon Alfa 2a (PEG) and Ribavirin (RBV) in Treatment-Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection and IL28B CC Genotype.
   
   For more information, click here.

   
   
4. Protocol: H9H-MC-JBAK
   
   Disease: Hepatocellular Carcinoma
   
   For more information, click here.
   
   
   

5. Protocol: AI444052.

   Protocol Title: A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C Genotype1.

   
   For more information, click here.